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An assay of bactericidal antibody has been developed to study the host response to
infection with Neisseria gonorrhoeae. This test for antibody was performed on the
sera of women who were exposed to N. gonorrhoeae but who did not become in-
fected, of patients with various types of genital infection with N. gonorrhoeae, and
of a small number of individuals with no history of gonorrhea. Antibody was found
in the sera of <31% of men and women with uncomplicated gonococcal infec-
tion. Prolonged mucosal infection with the gonococcus (>33 days) correlated with
the presence of bactericidal antibody. Bactericidal antibody was not detected in
95% of the specimens of acute-phase serum obtained from women with gonococcal
pelvic inflammatory disease. The convalescent-phase sera of 70% of women with
clinically severe pelvic inflammatory disease showed a rise in titer of bactericidal
antibody to the infecting strain of N. gonorrhoeae, whereas only 11% of the con-
valescent-phase sera of women with mild or moderately severe disease showed a simi-
lar rise.
The focus of most immunologic investigations of
infection due to Neisseria gonorrhoeae has been
on the use of serology as a diagnostic tool [1-4].
The host response to gonococcal infection has
received some attention in studies of antibody
response to gonococcal pili [4], but the role of
serum antibody as an immunologic defense
mechanism has been inadequately investigated.
For a study of systemic host response to infec-
tion with N. gcnorrhoeae, we thought it impor-
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tant to use an immunologic assay system in which
functioning antibody might be expected to have
a protective effect against the bacterium. Such a
serologic system is the complement-mediated bac-
tericidal system [5-7].
Studies by several groups have established the
susceptibility of N. gonorrhoeae to serum bac-
tericidal activity [8, 9]. Strains of this organism
have been shown to share multiple antigenic de-
terminants with Neisseria meningitidis [9]. Hu-
man immunity to N. meningitidis has been cor-
related with the presence of serum bactericidal
antibody to infecting strains of these organisms
[5]. Because of the established antigenic similari-
ties between these two bacteria and the known
susceptibility of N. gonorrhoeae to bactericidal
antibody, the bactericidal assay system is an ap-
propriate method for study of the role of serum
antibody in human immunity to gonococcal
infection.
This report describes the development of a test
for bactericidal antibodies to N. gonorrhoeae
and the use of this test for examination of sera
from exposed individuals who did not become
infected, individuals with various types of geni-
tal infection with N. gonorrhoeae, and a small
group of individuals with no history of gonococ-
cal infection.











Subjects. Laboratory personnel and patients
who agreed to participate and who gave written
informed consent were studied. All patients
were treated with appropriate antimicrobial
agents immediately after the initial specimens
were obtained.
(1) Laboratory volunteers. Five women and
one man who reported no history of gonococcal
infection volunteered serum samples. None of
the women had ever worked with N. gonorrho-
eae; however, the man had been working with
this organism. The women's sera were tested
against four strains of N. gonorrhoeae isolated
from patients with pelvic inflammatory disease
(patients no. 2, 8, 18, and 22, see table 4). The
man's serum was tested against six strains isolated
from asymptomatic women, three strains from
men with uncomplicated infection, three strains
from women with pelvic inflammatory disease,
one strain from a man with epididymitis, and two
strains (blood and joint isolates) from patients
with disseminated infection.
(2) Men with uncomplicated gonococcal ure-
thritis. Men who presented with a urethral dis-
charge from which N. gonorrhoeae was isolated
were studied. Sera obtained at the time of pre-
sentation and one to two weeks later were tested
against the homologous isolate of N. gonorrhoeae.
(3) Sexual contacts. .This group included
eight women with uncomplicated gonococcal in-
fection who were seen because they had had sex-
ual contact with a man infected with N. gonor-
rhoeae. Serum samples obtained immediately be-
fore treatment and on subsequent visits were
tested against the homologous isolate of N. gonor-
rhoeae obtained prior to treatment. None of
these women had complicated infection. Sera
from five women who were treated because they
were named as recent sexual contacts of men
with gonococcal urethritis, but whose endocer-
vical and anal cultures did not contain N. gonor-
rhoeae, were tested against the strain of N. gonor-
rhoeae isolated from their sexual partners.
(4) Women found to be infected during rou-
tine pelvic examination. This group included
women who had N. gonorrhoeae isolated from
an endocervical culture obtained during a rou-
tine pelvic examination and who were still in-
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fected with N. gonorrhoeae when they were re-
called for treatment. Serum samples obtained im-
mediately before treatment and on subsequent
visits were tested against the homologous iso-
late of N. gonorrhoeae obtained prior to treat-
ment. None of these women had complicated in-
fection.
(5) Women with pelvic inflammatory disease.
Nonpregnant women with acute pelvic inflam-
matory disease from whom N. gonorrhoeae was
isolated from cervical cultures were studied.
Samples of serum obtained before treatment and
periodically after the completion of treatment
were tested against the homologous isolate of N.
gonorrhoeae obtained before treatment.
A repeat physical examination was done on the
day after the initiation of treatment; most pa-
tients were reexamined by the same physician.
During this examination, the degree of lower
abdominal tenderness, lower abdominal rebound
tenderness, and pain on motion of the cervix
was graded as severe, moderate, mild, or absent
according to the following arbitrary criteria: se-
vere if discomfort elicited by minimal pressure
was agonizing as evidenced by facial expression
and reaction to the stimulus; moderate if discom-
fort was easily elicited but was not severe, as ob-
served from the patient's facial expression and
reaction to the stimulus; mild if the discomfort
was not evident by observation of the patient's
facial expression or reaction to the stimulus, i.e.,
if the examiner had to ask the patient if there was
discomfort; and absent if no discomfort resulted
from the stimulus.
(6) A subject with epididymitis. Sera ob-
tained three and 10 weeks after onset of symp-
toms of gonococcal epididymitis in one man
were tested against the isolate of N. gonorrhoeae
obtained from his urethra before treatment.
I den tification and handling of N. gonorrhoeae.
All subjects except the six laboratory volun-
teers were examined for N. gonorrhoeae. Cul-
tures obtained before the initiation of treatment
and as part of each subsequent examination were
inoculated immediately onto appropriate media
and were examined after incubation for 24 and
48 hr at 36.5 C in a candle jar. Colonies with
typical morphology that gave a positive oxidase
reaction with N,N-dimethyl-p-phenylene dia-
mene HCl and that contained gram-negative









Bactericidal Antibody to N. gonorrhoeae
cocci were identified as N. gonorrhoeae. Strains
isolated from patients with pelvic inflammatory
disease and disseminated gonococcal infection
were further characterized as N. gonorrhoeae by
typical sugar fermentation patterns. Strains were
stored frozen at -70 C in trypticase soy broth:
glycerol (4: 1, vol/vol).
Colonial types (T) were maintained as T3 or
T4 [10, II]. T3 and T4 colonies were used in
these experiments to avoid the agglutination that
occurs in TI and T2 suspensions [12] and pre-
cludes accurate colony counts. Furthermore, the
problem of colonial stability was avoided by use
of T3 and T4 colonies in broth culture. It has
also been shown that bactericidal antibody is di-
rected against all gonococcal types [9]. All strains
were tested in the bactericidal assay within 10
passages of isolation; frozen cultures were
thawed and inoculated onto a chocolate agar
plate. After incubation overnight at 36 C in a
candle jar, the plate was swabbed with a moist-
ened cotton-tipped applicator, and organisms
were inoculated into 25 ml of a broth defined
by Morse and Fitzgerald [13] in a 250-ml nephel-
ometry flask to an OD of 0.03 units measured in a
Coleman Jr. spectrophotometer (Coleman Instru-
ment Corp., "Maywood, Ill.) at 650 nm and incu-
bated aerobically at 37 C with continuous stirring
by a magnetic apparatus. Organisms were har-
vested during the early logarithmic phase of
growth when the OD was 0.1 units. This value
was obtained within 2.5-4 hr after inoculation of
the flask and was found to correspond to a con-
centration of approximately 3 X 108 organisms/
ml. Comparison of chamber counts of bacteria to
numbers of cfu revealed that >95C;o of the bacteria
present were viable.
Bactericidal assay. The bactericidal test em-
ployed in these studies was a modification of the
procedure described by Roberts [14] and Gold
and Wyle [I5] for N. meningitidis. Reaction mix-
tures were set up in 12- X 75-mm glass tubes
with gauze plugs. Test mixtures contained 0.05
ml of complement, 0.05 ml of test serum, 0.05 ml
of gonococci, and 0.1 ml of diluent.
For preparation of complement freshly drawn
human blood was allowed to clot at room temper-
ature (about 24 C) for 15 min. The serum was
separated by centrifugation at 3,000 g for 10 min
at 24 C, and the separated serum was immediate-
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ly placed in an ice bath. This serum was ab-
sorbed with test gonococci in groups of five
strains from heavily streaked plates that had been
incubated overnight (5 ml of serum per plate)
[16]. The absorption was carried out in the ice
bath for I hr with frequent stirring of the suspen-
sion. After absorption the organisms were re-
moved by centrifugation at 4 C, and the com-
plement source was sterilized by passage through
a Millipore filter (pore size, 0.45 /Lm; Millipore
Corp., Bedford, Mass.) and was stored immedi-
ately at -70 C.
Complement was thawed only once and was
used only in bactericidal assays involving the
same strains against which it had been absorbed.
Separate experiments revealed that sera ab-
sorbed by this technique and used as a comple-
ment source did not inhibit the bactericidal re-
action as compared with the same sera, unab-
sorbed. Thus quantities of antigen sufficient for
the inhibition of bactericidal antibody activity
in the test sera did not remain in the comple-
ment source. Several tests with several strains
were performed to detect decreases in antibody
titers in known positive sera with both absorbed
and unabsorbed complement sources. No such
decreases were observed.
All serum specimens from each patient which
had been stored at -20 C were tested simultane-
ously with use of serial dilutions to 1:1,000 to
check for possible interference in the bactericidal
reaction by blocking antibody [17]. Interference
was not observed. Sera were diluted with the
media in which the organisms were grown.
N. gonorrhoeae were harvested as described
in broth containing 3 X 108 organisms/rnl, and
dilutions with growth media were made to ob-
tain an inoculum containing 3 X 104 organisms/
ml. A volume of 0.05 ml was inoculated into each
reaction mixture.
The growth medium was used as the diluent
in all experiments. It was found that concen-
trations of medium used in these experiments did
not interfere with complement activity sufficient-
ly to affect the amount of killing in the bacteri-
cidal system. Furthermore, a typical complement
source diluted with media-saline (80% vol/vol,
the maximal concentration of media used in the
bactericidal test) was found to contain 72 CH50
units/rnl [18] (I CH50 unit lyses 50% of sensitized










red blood cells), whereas the same sera diluted
with saline contained 110 CHaO units /ml. Doubling
of the concentration of complement in the bacte-
ricidal test system did not change the amount of
bacterial killing.
The reaction mixtures were incubated aero-
bically at 37 C in a rotary-shaker water bath.
Viable colonies were counted at 0 and 30 min
by plating of duplicate 0.025-ml samples of each
reaction mixture onto chocolate agar. In prelimi-
nary kinetic studies with use of hyperimmune
rabbit sera, 100% of the bacteria were found to
be killed by 10-15 min. An active complement
control tube without immune serum and a heat-
inactivated (56 C for 30 min) complement con-
trol tube with the patient's serum were also test-
ed in each experiment. In addition, a known
positive rabbit serum was tested in each experi-
ment as a control for the presence of adequate
complement levels.
For analysis of results, bactericidal activity was
expressed in terms of the percentage of bac-
teria surviving in the test mixture divided by
the percentage surviving in the complement
control. The following criteria for killing had to
be met: (1) <50% survival in the 30-min ali-
quot when compared with survival in the zero-
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time sample; (2) a value of <50% when the
percentage of survival in the test mixture was
divided by the percentage of survival in the ac-
tive complement control; (3) at least 90% sur-
vival at 30 min in the active and inactive com-
plement controls (this value was actually nearly
always> 100%). These criteria ensured that ag-
glutination was not a significant factor in reduc-
tion of counts at 30 min.
Duplicate plating of 0.025-ml samples result-
ed in variations in colony counts of 10%-15%.
Killing in low-titered sera (1:5) was always found
to be significant when compared with killing in
controls, if it was assumed that the number of or-
ganisms per unit volume followed a Poisson dis-
tribution. Survival of ~10 organisms in the assays
of these sera always represented killing of > I
10glO'
Results
Laboratory volunteers. One sample of hu-
man serum from a man who had been working
with N. gonorrhoeae was bactericidal to four of
15 isolates of N. gonorrhoeae (three from pa-
tients with uncomplicated infection and one
from the man with epididymitis). Sera from five
Table 1. Titers of bactericidal antibody to the homologous isolates of Neisseria gonorrhoeae in sera from 13
men with uncomplicated gonococcal urethritis.
No. of prior Duration of Sera from
episodes of symptoms of day of presentation Late sera
Patient gonococcal urethritis Antibody No. of cfu ± range Day Antibody No. of cfu ± range
no. urethritis* (days) titer t (to, t 30 ):l: obtained titer] (to, t30)+
5921 1 6 50 233 ± 0, 1 ± 1 15 50 208 ± 0,0
5965 1 9 303 ± 32,364 ± 12 11 281 ± 8,563 ± 0
5988 2 1 215 ± 0, 269 ± 32 14 119 ± 11, 235 ± 21
5993 0 >60 50 158 ± 11, 1 ± 1 11 50 189 ± 6, 3+ 1
6012 2 5 141 ± 24,266 ± 34 11 5 135 ± 1, 39 ± 10
6658 1 5 149 ±26, 191 ± 4 11 182 ± 23,192 ± 6
6730 3 NR§ 106 ± 7, 176 ± 3 15 135 ± 38,175 ± 15
6744 0 NR 125 ± 14, 270 ± 53 13 182 ± 48,305 ± 23
3750 1 4 155 ± 13, 220 ± 17 11 175±20,248± 7
13616 4 2 5 89 ± 16,0 8 5 103 ± 2, 2± 1
13621 0 3 153±11,168± 7 8 111 ± 34, 215 ± 15
13649 2 3 5 181 ± 23, 3± 1 9 5 135±10, 1 + 1
18859 1 3 185 ;t 8,208±21 8 195 ± 10, 255 ± 10
*As recorded by the clinic or reported by the patient, whichever was greater.
iTiters are expressed as the reciprocal of the highest dilution at which killing occurred (see Materials and Methods). (-) =no
antibody detected.
:j:Mean no. of cfu ± range in 25-IJI samples of the reaction mixture with indicated dilution of test serum at the start of the
experiment (to) and after incubation for 30 min (t30)'
§ NR = not recorded.
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women who had no history of gonococcal infec-
tion lacked antibody to each of four isolates of
N. gonorrhoeae obtained from women with acute
pelvic inflammatory disease.
Men with uncomplicated gonococcal urethri-
tis. As shown in table 1, four (31%) of 13 men
with uncomplicated gonococcal urethritis had
bactericidal antibody in their pretreatment se-
rum to the infecting strain of N. gonorrhoeae.
None of thefour showed a subsequent change in
titer. Only one (no. 6012) of the nine men who
were initially seronegative developed bactericidal
antibody.
Sexual contacts. The results of the bacteri-
cidal antibody determinations performed on sera
from women with uncomplicated gonococcal in-
fection who were treated because of sexual con-
tact with a man with gonococcal urethritis are
summarized in table 2. Two of these women had
antibody in their pretreatment serum to the
strain of N. gononhoeae that had been isolated
from their endocervical canals. There were no
changes in titer in the subsequent sera.
Of five women who had had sexual contact
with a man with gonococcal urethritis but whose
endocervical cultures did not contain gonococci,
one had serum that was bactericidal for the strain
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of N. gonorrhoeae that had been isolated from
her sexual partner.
Women found to be infected during routine
pelvic examination. Table 3 shows the bacteri-
cidal titers in the sera of the women who were
treated because they were found to have N. gon-
orrhoeae in an endocervical culture obtained
during a routine pelvic examination. Of nine
women who were recalled for treatment within
33 days after N. gonorrhoeae had been isolated,
one patient had bactericidal antibody in her pre-
treatment serum to the homologous strain of
N. gonorrhoeae isolated before treatment. In con-
trast, four of five women for whom the in-
terval between the initial isolation of N. gonor-
rhoeae and treatment was >33 days had bacteri-
cidal antibody (P = 0.016; Fisher's exact test).
This finding suggests that prolonged asympto-
matic carriage of N. gonorrhoeae is associated
with the development of bactericidal antibody.
Two of these women (no. 13558 and 7034) de-
veloped rises in titer at 32 and 50 days, respec-
tively, after their initial culture.
Patients with locally invasive disease. Nine-
teen women with gonococcal pelvic inflamma-
tory disease were studied (table 4). Sera ob-
tained before treatment and seven to 73 days af-
Table 2. Titers of bactericidal antibody to the homologous isolates of Neisseria gonorrhoeae in sera from eight
women with uncomplicated gonococcal infection who were brought to medical attention because of sexual con-
tact with infected men.
No.ot
prior epi-





Patient presen- infect- Antibody No. of cfu ± range
no. tation tion" titer] (to, t30)+ Day obtained
6836 1 2 90 ± 4, 130 ± 4 7,15,212,219
6818 8 4 46 ± 6, 61 ± 5 14,20
7022 7 0 81 ± 4, 93 ± 3 6, 13
7086 2 0 57 ± 4, 77± 8 8,17
6861 20 0 114±10, 76 ± 2 8,17
6817 NR§ 0 42 ± 8, 69 ± 3 9,16
6885 NR 0 500 176 ±16, 19 ± 6 10,17






No. of cfu ± range
(to, t30)+
100 ± 3,122 ±10
55 ± 5, 80 ± 12
68 ± 6, 69 ± 6
57 ± 8, 77 ± 3
106 ± 14, 71 ± 1
51 ± 3, 88 ± 12
216 ± 21, 25 ± 0
84 ± 6, 40 ± 3
*As recorded by the clinic or reported by the patients, whichever was greater.
tTiters are expressed as the reciprocal of the highest dilution at which killing occurred (see Materials and Methods). (-) = no
antibody detected.
+Mean no. of cfu ± range in 25-,u1 samples of the reaction mixture with indicated dilution of test sera at the start of the exper-
iment (to) or after incubation for 30 min (t30)' In late sera results are given for the earliest available late serum sample; however,
titers for all late sera from each patient were the same.
§ NR = not recorded.
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Table 3. Titers of bactericidal antibody to the homologous isolates of Neisseria gonorrhoeae in sera from 14
women with uncomplicated gonococcal infection found during routine pelvic examination and who were still




initial episodes Late sera
culture of gono-
day of presentation Day obtained
Patient to presen- coccal Antibody No. of cfu ± range after initial Antibody No. of cfu ± range
no. tation infection" titer'] (to' t 30):I: culture titer'] (to' t30):I:
13520 11 2 81 ± 19, 91 ± 24 19 42 ± 4, 81 ± 5
7090 11 0 81 ± 11, 54 ± 11 27 50 ± I, 58 ± 2
7065 12 0 79 ± I, 109 ± 4 20,27 81 ± 8, 102 ± 2
6860 15 0 10 51 ± I, 1 ± 1 23,30 10 33± 10, 3± 1
13556 15 0 0 194 ±62, 254 ± 0 25,32 231 ± 158,371 ±61
3834 21 1 0 45 ± 1, 55 ±22 NA§
3870 21 1 0 50 ± I, 71 ± 8 NA
13558 24 0 0 78 ± 3, 108 ± 3 32,39 5 79 :t 9,0
7044 33 0 0 66 ± 6, 75 ± 15 NA
13560 36 1 5 97 ± 16, 1 ± 1 44 5 101 ± 2, 3± 1
6588 38 2 58 ± 13, 49 ± 8 52 46 ± 7, 58 ±27
7034 43 0 5 61 ± 8, 6± 0 50 50 94 ± I, 20 ± 8
7081 46 1 5 30 ± 4,0 NA
6863 75 1 5 98 ±49, 41 ± 24 NA
*As recorded by the clinic or reported by the patients, whichever was greater.
tTiters are expressed as the reciprocal of the highest dilution at which killing occurred (see Materials and Methods). (-) = no
antibody detected.
:l:Mean no. of cfu ± range in 25-1.11 samples of the reaction mixture with indicated dilution of test sera at the start of the exper-
iment (to) or after incubation for 30 min (t30). In late sera results are given for the earliest available late serum sample; however,
titers for all late sera from each patient were the same.
§ NA =no t available.
tel' the initiation of treatment were tested against
the strain of N. gonorrhoeae that was isolated
from the endocervical canal before treatment was
initiated. One woman had bactericidal antibody
to the homologous isolate of N. gonorrhoeae in .
her acute-phase serum specimen. Eight of the 19
patients with pelvic inflammatory disease devel-
oped antibody in their convalescent-phase sera
or showed a rise in antibody titer.
The severity of illness on the second day of
treatment as defined by the aforementioned ar-
bitrary clinical criteria correlated with the de-
velopment of bactericidal antibody. Seven (70%)
of 10 patients with severe illness developed anti-
body or showed a rise in titer compared with only
one (12.5%) of eight women who had mild or
moderate illness (P = 0.022; Fisher's exact test).
Paired sera from one man with epididymitis
were tested against the strain of N. gonorrhoeae
isolated from his urethra. A serum sample ob-
tained when he presented to his physician
(three weeks after the onset of symptoms) showed
a bactericidal antibody titer of 1:10. Serum ob-
tained seven weeks later had a titer of 1:40.
Discussion
The bactericidal test described herein repre-
sents a modification of tests used by other inves-
tigators for classical studies of immunity to N.
meningitidis [5, 6, 15] and to Haemophilus in-
[luenzae [7]. These investigators, using early to
midlogari thmic phase broth cultures, have corre-
lated the presence of serum bactericidal activity
with protection against invasive disease. In ad-
dition, their data have shown that most infected
individuals lack bactericidal antibody [5, 6] and
that bactericidal antibody can be acquired
through mucosal colonization [5, 6].
We also used early to midlogarithmic phase
broth cultures and have shown that the serum of
a male volunteer who had no history of gono-
coccal infection was bactericidal to only four of
15 strains of N. gonorrhoeae. Antibody to these
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strains may have developed in this individual
as a result of his work with the organisms. Bac-
tericidal activity against four clinical isolates was
absent from the sera of five other female volun-
teers. These findings differ from those of School-
nik et al. [19] who found that the sera of 20 nor-
mal people without previous gonococcal infec-
tion had titers of bactericidal antibody of 1:16-
'1 :8,192 to six strains of N. gonorrhoeae isolated
from patients with uncomplicated gonorrhea.
Bactericidal tests are complex, and a number
of variables including growth medium [20], phase
of growth [14], number of times and the condi-
tions under which the organism has been subcul-
tured [21, 22], and type of diluent [23-25] can
profoundly influence the results. In addition, the
source of complement is another potential vari-
able, although in our assays fresh sera either ab-
sorbed with test gonococci or unabsorbed were
found to be adequate sources of complement.
Another group of investigators [8, 22, 26] has
studied both broth-grown and plate-grown organ-
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isms in the bactericidal test. With use of broth-
grown gonococci, each of the sera of eight nor-
mal individuals was bactericidal to from one to
four of 10 genital isolates of N. gonorrhoeae from
outpatients [8]. In the same study, an addition-
al sample of normal human serum was bacteri-
cidal to 21 of 60 gonococcal strains. In another
study [22],. when suspensions of plate-grown or-
ganisms were used (different strains from those in
the prior study), after exposure to normal hu-
man serum, 70% of those organisms grown
on solid media containing prostatic extract sur-
vived, whereas only 2% of organisms grown on
colonial type media survived [10, 12]. Thus, un-
less bactericidal tests are done under identical
conditions, results are difficult to compare.
The implications of our results should be con-
sidered in relation to the role of immunity to the
other major pathogenic gram-negative coccus,
N. meningitidis, since this organism has been
studied more extensively. We have found that
serum bactericidal antibody to N. gonorrhoeae
Table 4. Titers of bactericidal antibody to infecting strains of Neisseria gonorrhoeae in acute- and convales-
cent-phase sera of 19 women with pelvic inflammatory disease.
Previous
Acute-phase sera Convalescent-phase sera
history of Anti- Day Anti-
Patient gonococcal body No. of efu ± range obtained after body No. of cfu ± range Severity
no. infection titer" (to, t 3o)t presentation titer" (to, t30)t of disease+
302 Yes 43 ± 10, 91 ± 17 60,71 50 ± 6, 43 ± 7 m
331 Yes 286 ± 0,365 ± 5 13,52 247 ± 43, 250 ± 25 m
6 No 219 ±58, 371 ±122 16 207 ± 84, 248 ± 32 M
8 Yes 218 ± 21,376 ± 0 10 210 ± 11, 302 ± 6 M
11 No 277 ± 61,358 ± 16 30 197 ± 18,273 ± 73 M
332 Yes 151 ± 14, 239 ± 5 50 169 ± 16,290 ± 33 M
333 Yes 121 ± 9,158 ± 9 14,48 161 ± 20, 195 ± 15 M
336 No 5 247 ± 20, 13 ± 3 12,32 10 300±13, 28 ± 3 M
20 No 181 ± 42, 228 ± 45 7 172 ±34, 276 ± 7 NR
1 No 123 ± 19,158 ± 23 56 5 219 ± 18, 2± 2 S
2 No 103 ± 20, 282 ± 18 48 5 95 ± 1, 12 ± 0 S
5 No 201 ± 18,185 ± 0 39 10 295 ± 11, n ± 15 S
17 No 40 ± 8, 87 ± 6 18 135 ± 18,102 ± 0 S
18 Yes 71 ± 17, 160 ± 8 73 5 583 ± 27,256 ± 35 S
22 No 74 ± 8, 191 ± 17 15 114 ± 8,360 ± 53 S
24 No 273 ± 0,313 ± 37 14 >40 245 ± 3, O± 0 S
305 No 160 ± 10,223 ± 10 17 152 ± 3,226 ± 23 S
334 No 165 ± 38, 127 ± 11 12,26 10 143 ± 52, 36 ± 8 S
335 No 42 ±26, 197 ± 15 12,37 5 143 ± 20, 25 ± 8 S
*Titers are expressed as the reciprocal of the highest dilution at which killing occurred (see Materials and Methods). (-) = no
antibody detected.
tMean no. of cfu ± range in 25-,u1 samples of the reaction mixture with indicated dilution of test sera at the start of the exper-
iment (to) or after incubation for 30 min (t30)' In convalescent-phase sera results are given for the earliest available convalescent
serum sample; however, titers for all late convalescent sera from each patient were the same.
ts =severe; M = moderate; m =mild; and NR = not recorded.










may be present in the serum of patients with
mucosal infection. Serum bactericidal antibody
induced by specific polysaccharide vaccines of N.
meningitidis does not prevent acquisition of mu-
cosal infection and does not eliminate the car-
rier state, although the rate of carriage in a popu-
lation is reduced by approximately 50% [27]. We
have also found that, as with the meningococcus
[5, 6, 28], mucosal infection with the gonococcus
is associated with the development of serum bac-
tericidal antibody. Thiseffect was seen primarily
in individuals who had been infected for longer
than a month.
Our data and those of others [8] suggest that
a minority of individuals have bactericidal anti-
body to N. gonorrhoeae; in contrast, the ma-
jority of adults have serum bactericidal antibody
to N. meningitidis [6]. The apparent differences
in prevalence of antibody to these two bacteria
may be in part related to the extent of exposure
to these organisms, failure of carriage to induce
antibody in all cases, or lack of sensitivity of the
gonococcal assay as compared with that of the
meningococcal assay. Nasopharyngeal infection
with N. meningitidis is a far more common event
than infection with N. gonorrhoeae [29]. The dif-
ference in the prevalence of bactericidal anti-
body to these two organisms suggests that the
cross-reactive antigens shared by these two organ-
isms [9] may not be important in natural im-
munity. In addition, development of bacteri-
cidal antibody in most patients with uncompli-
cated infection and mild or moderate pelvic in-
flammatory disease may have been curtailed by
early antibiotic therapy [30-32]. Bactericidal an-
tibody was seen, however, in patients with either
prolonged asymptomatic carriage or severe symp-
tomatic disease and may have been due to pro-
longed antigenic stimulation or larger antigenic
loads.
\Ve have also shown that only one (5.3%) of
19 women who were treated for gonococcal pel-
vic inflammatory disease had serum bactericidal
antibody to the infecting strain of N. gonorrho-
eae at the time of presentation for treatment.
This finding might suggest that the presence of
serum bactericidal antibody to the homologous
isolate protects against ascending infection; how-
ever, only two (25%) of eight sexual contacts
of men with gonococcal urethritis who developed
Kasper, Rice, and McCormack
mucosal infection without pelvic inflammatory
disease had serum bactericidal antibody. Thus,
although it is conceivable that bactericidal an-
tibody may help protect against invasive infec-
tion, other host and/or organism factors must
also be involved.
Antigenic differences in bacterial strains may
be significant in the pathogenesis of infection
[33]. Such differences between strains of N.
meningitidis certainly playa vital role in the vir-
ulence of that bacterium. Strains of N. gonor-
rhoeae isolated from patients with disseminated
gonococcal infection have been shown to be more
susceptible to penicillin than strains isolated
from individuals who had uncomplicated gono-
coccal infection [34]. In addition, strains that
cause severe illness may have antigenic determi-
nants or growth requirements different from
those of nonpathogenic strains [35, 36]. The role
of local antibodies in gonococcal infection also
needs further evaluation [37, 38].
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